Spondyloarthritis & psoriatic arthritis
Genetically Proxied Interleukin‐13 Inhibition Is Associated With Risk of Psoriatic Disease: A Mendelian Randomization Study
Authors' conclusion
We provide supportive genetic evidence that IL-13i is linked to increased risk of PsA and psoriasis.
Study context
- Population
- Outcome genetic data from studies of psoriatic arthritis (PsA), psoriasis and related SpA traits; exposure instrument from a study of 563,946 individualsup to 10,588 cases and 209,287 controls
- Comparison
- Genetically proxied IL-13 inhibition and risk of PsA and psoriasis
- Outcome
- Risk of PsA and psoriasis
Methodological detailscolocalization analysis, replication with circulating IgE and independent outcome data, individual-level replication in UK Biobank
- Colocalization analysis
- Replication with circulating IgE and independent outcome data
- Individual-level replication in UK Biobank
Main finding
As reported in the abstract
Estimate (95% CI)P value
Genetically proxied IL-13i
OR (PsA) 37.39(11.52–121.34)
P = 1.64 × 10-9Genetically proxied IL-13i
OR (psoriasis) 20.08(4.38–92.01)
P = 1.12 × 10-4Further findings
Crohn disease, ulcerative colitis, AS, iritis
- No consistent associations
Genetic confounding (colocalization)
- No strong evidence of genetic confounding for psoriatic disease
Replication
- Results replicated using circulating IgE for exposure, independent outcome data and individual-level data
Original publication
Genetically Proxied Interleukin‐13 Inhibition Is Associated With Risk of Psoriatic Disease: A Mendelian Randomization Study. Arthritis Rheumatol. Published 31 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →